245 related articles for article (PubMed ID: 34833063)
21. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer.
Wilbur HC; Durham JN; Lim SJ; Purtell K; Bever KM; Laheru DA; De Jesus-Acosta A; Azad NS; Wilt B; Diaz LA; Le DT; Wang H
Cancer Res Commun; 2023 Aug; 3(8):1672-1677. PubMed ID: 37645623
[TBL] [Abstract][Full Text] [Related]
22. Drug Delivery Systems Based on Polymeric Micelles and Ultrasound: A Review.
Tanbour R; Martins AM; Pitt WG; Husseini GA
Curr Pharm Des; 2016; 22(19):2796-807. PubMed ID: 26898742
[TBL] [Abstract][Full Text] [Related]
23. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
Li Y; Chen Y; Li J; Zhang Z; Huang C; Lian G; Yang K; Chen S; Lin Y; Wang L; Huang K; Zeng L
Cancer Sci; 2017 Jul; 108(7):1493-1503. PubMed ID: 28444967
[TBL] [Abstract][Full Text] [Related]
24. Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells.
Trabulo S; Aires A; Aicher A; Heeschen C; Cortajarena AL
Biochim Biophys Acta Gen Subj; 2017 Jun; 1861(6):1597-1605. PubMed ID: 28161480
[TBL] [Abstract][Full Text] [Related]
25. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Heinemann V
Semin Oncol; 2002 Dec; 29(6 Suppl 20):9-16. PubMed ID: 12577228
[TBL] [Abstract][Full Text] [Related]
26. Selecting chemotherapy for pancreatic cancer: Far away or so close?
Shi S; Yu X
Semin Oncol; 2019 Feb; 46(1):39-47. PubMed ID: 30611527
[TBL] [Abstract][Full Text] [Related]
27. Nanocarriers for anticancer drugs--new trends in nanomedicine.
Drbohlavova J; Chomoucka J; Adam V; Ryvolova M; Eckschlager T; Hubalek J; Kizek R
Curr Drug Metab; 2013 Jun; 14(5):547-64. PubMed ID: 23687925
[TBL] [Abstract][Full Text] [Related]
28. Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
Deodhar S; Dash AK; North EJ; Hulce M
AAPS PharmSciTech; 2020 Aug; 21(6):231. PubMed ID: 32778980
[TBL] [Abstract][Full Text] [Related]
29. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
30. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
[TBL] [Abstract][Full Text] [Related]
31. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
32. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
[TBL] [Abstract][Full Text] [Related]
33. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
[TBL] [Abstract][Full Text] [Related]
34. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
[TBL] [Abstract][Full Text] [Related]
35. [Gemcitabine-based combinations in inoperable pancreatic cancers].
Louvet C; André T; Artru P
Bull Cancer; 2002 Aug; 89 Spec No():S96-101. PubMed ID: 12449038
[TBL] [Abstract][Full Text] [Related]
36. Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress.
Ortíz R; Quiñonero F; García-Pinel B; Fuel M; Mesas C; Cabeza L; Melguizo C; Prados J
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33923200
[TBL] [Abstract][Full Text] [Related]
37. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Mizusawa J; Fukutomi A; Katayama H; Ishii H; Ioka T; Okusaka T; Ueno H; Ueno M; Ikeda M; Mizuno N; Ozaka M; Fukuda H; Furuse J;
Pancreatology; 2018 Oct; 18(7):841-845. PubMed ID: 30075908
[TBL] [Abstract][Full Text] [Related]
38. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.
Woo W; Carey ET; Choi M
Onco Targets Ther; 2019; 12():1455-1463. PubMed ID: 30863113
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticles in Combating Cancer: Opportunities and Limitations. A Brief Review.
Pedziwiatr-Werbicka E; Horodecka K; Shcharbin D; Bryszewska M
Curr Med Chem; 2021; 28(2):346-359. PubMed ID: 32000637
[TBL] [Abstract][Full Text] [Related]
40. Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging.
Rapoport N; Kennedy AM; Shea JE; Scaife CL; Nam KH
Mol Pharm; 2010 Feb; 7(1):22-31. PubMed ID: 19899813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]